Key Event Details
- Glenmark Specialty S.A. launched RYALTRIS® Nasal Spray in Brazil for the treatment of moderate to severe symptoms associated with allergic rhinitis (AR) in adults and adolescents of 12 years of age and older
- The launch follows regulatory approval granted by the Brazilian Health Regulatory Agency, Agência Nacional de Vigilância Sanitária (ANVISA) earlier in 2026
- The product is the first olopatadine-containing intranasal combination therapy in Brazil, combining an antihistamine (olopatadine hydrochloride) and a corticosteroid (mometasone furoate) in a single nasal spray
Market Context and Impact
- Allergic rhinitis affects an estimated 20–30% of the Brazilian population, equivalent to nearly 40–60 million people
- Brazil represents the largest healthcare market in Latin America, providing strategic growth opportunity
- RYALTRIS® is Glenmark's first globally commercialized branded innovative product and has been approved in 57 markets worldwide including the United States, European Union, United Kingdom, Australia, South Korea, Russia, and China
Strategic Rationale
According to Marco Cerato, Executive Vice President & Global Head – Innovative Business, the launch "marks a significant milestone for our innovative respiratory portfolio and reflects our continued commitment to advancing respiratory care through science-led innovation and a patient-centric approach."
Company Background
Glenmark Pharmaceuticals Ltd. is a global, research‐led pharmaceutical company with 11 world-class manufacturing facilities across four continents, six R&D centres, and commercial footprint in 80+ countries. The company focuses on respiratory, dermatology, and oncology therapeutic areas and is positioned among the Top 100 biopharmaceutical companies globally by pharmaceutical sales for 2024.